BARI, Alessia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.751
EU - Europa 4.235
AS - Asia 3.231
SA - Sud America 530
AF - Africa 116
OC - Oceania 23
Continente sconosciuto - Info sul continente non disponibili 8
Totale 17.894
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.625
GB - Regno Unito 1.785
CN - Cina 1.063
SG - Singapore 972
IT - Italia 632
HK - Hong Kong 464
BR - Brasile 430
DE - Germania 398
SE - Svezia 356
FR - Francia 221
VN - Vietnam 195
RU - Federazione Russa 188
FI - Finlandia 175
UA - Ucraina 172
TR - Turchia 152
BG - Bulgaria 71
CA - Canada 71
ID - Indonesia 70
KR - Corea 69
IN - India 60
MA - Marocco 48
AR - Argentina 42
BE - Belgio 31
LT - Lituania 29
IE - Irlanda 28
JP - Giappone 27
MX - Messico 27
PL - Polonia 27
ZA - Sudafrica 27
BD - Bangladesh 23
ES - Italia 23
AU - Australia 19
AT - Austria 18
PH - Filippine 18
CZ - Repubblica Ceca 17
NL - Olanda 17
PK - Pakistan 17
EC - Ecuador 16
IR - Iran 13
AE - Emirati Arabi Uniti 11
CL - Cile 11
IQ - Iraq 10
MY - Malesia 10
CH - Svizzera 9
CO - Colombia 9
SA - Arabia Saudita 9
UZ - Uzbekistan 9
EG - Egitto 8
KE - Kenya 8
JO - Giordania 7
PT - Portogallo 7
AZ - Azerbaigian 6
EU - Europa 6
GR - Grecia 6
NO - Norvegia 6
RO - Romania 6
BO - Bolivia 5
KZ - Kazakistan 5
PY - Paraguay 5
TZ - Tanzania 5
VE - Venezuela 5
BZ - Belize 4
CR - Costa Rica 4
GH - Ghana 4
KG - Kirghizistan 4
NZ - Nuova Zelanda 4
PE - Perù 4
AL - Albania 3
DO - Repubblica Dominicana 3
GP - Guadalupe 3
HU - Ungheria 3
IL - Israele 3
JM - Giamaica 3
LB - Libano 3
NG - Nigeria 3
PA - Panama 3
RS - Serbia 3
SV - El Salvador 3
UY - Uruguay 3
BH - Bahrain 2
DM - Dominica 2
ET - Etiopia 2
NP - Nepal 2
TW - Taiwan 2
UG - Uganda 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AO - Angola 1
CY - Cipro 1
DZ - Algeria 1
GA - Gabon 1
GT - Guatemala 1
HN - Honduras 1
HR - Croazia 1
IM - Isola di Man 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
MG - Madagascar 1
MU - Mauritius 1
NI - Nicaragua 1
Totale 17.886
Salva come PNG Salva come JPEG
Città #
Southend 1.448
Fairfield 1.059
Ashburn 879
Santa Clara 867
Woodbridge 702
Singapore 641
Houston 505
Chandler 497
Hong Kong 462
Seattle 442
Wilmington 399
Cambridge 380
Ann Arbor 327
Jacksonville 314
Dearborn 261
Hefei 252
Nyköping 246
Beijing 233
Chicago 192
London 189
Modena 181
Los Angeles 178
San Jose 156
New York 135
Helsinki 106
San Diego 106
Shanghai 96
Frankfurt am Main 82
Salt Lake City 82
Princeton 76
The Dalles 74
Ho Chi Minh City 72
Sofia 70
Moscow 69
Seoul 65
Izmir 63
Council Bluffs 61
Eugene 61
Munich 60
Jakarta 54
São Paulo 54
Milan 47
Hanoi 44
Casablanca 40
Bremen 35
Buffalo 35
Dallas 34
Elk Grove Village 34
Columbus 33
Redwood City 33
Bologna 31
Fremont 31
Rome 29
Brussels 27
Falls Church 27
Phoenix 26
Boardman 25
Dublin 25
Tampa 25
Warsaw 23
Montreal 21
Dong Ket 20
Sterling 19
Turku 19
Toronto 18
Denver 17
Nanjing 17
Norwalk 17
Orem 17
Des Moines 16
Johannesburg 16
Lancaster 16
Tokyo 16
Chengdu 15
Guangzhou 15
Poplar 15
Brooklyn 13
Nuremberg 13
Rio de Janeiro 13
San Giuliano Milanese 13
Stockholm 13
Detroit 11
Latina 11
Paris 11
Redondo Beach 11
Rho 11
Atlanta 10
Boston 10
Dulles 10
Genoa 10
Kunming 10
Miami 10
Ottawa 10
San Mateo 10
Buenos Aires 9
Dhaka 9
Parma 9
Sydney 9
Trabzon 9
Belo Horizonte 8
Totale 13.327
Salva come PNG Salva come JPEG
Nome #
Therapy-related myeloid neoplasm in non-hodgkin lymphoma survivors. 584
Absolute monocyte count at diagnosis could improve the prognostic role of early FDG-PET in classical Hodgkin lymphoma patients 466
Anthracydine-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma 453
Incidence, clinical characteristics and survival of malignant lymphomas: a population-based study from a cancer registry in northern Italy. 435
Monocytosis has adverse prognostic significance and impacts survival in patients with T-cell lymphomas 401
A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up 391
Clusterin enhances AKT2-mediated motility of normal and cancer prostate cells through a PTEN and PHLPP1 circuit 385
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program 370
The undergraduate nursing student evaluation of clinical learning environment: an Italian survey [La valutazione dell'ambiente di apprendimento clinico da parte degli studenti del Corso di Laurea in Infermieristica: una indagine italiana] 368
Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: A 16-year follow-up study 361
Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) 355
Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study 348
Defining the best cut-off value for lymphopenia in diffuse large B cell lymphoma treated with immuno-chemotherapy 337
Activity of BKM120 and BEZ235 against lymphoma cells 335
Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: Final results of a phase II study conducted by the Fondazione Italiana Linfomi 331
Empathic attitudes among nursing students: a preliminary study 330
Absolute monocyte count and lymphocyte-monocyte ratio predict outcome in nodular sclerosis Hodgkin lymphoma: Evaluation based on data from 1450 patients 329
Combination of low doses of Enzastaurin and Lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines 321
The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines 314
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study 308
A concise review of lenalidomide therapy for follicular lymphoma 304
The classic prognostic factors in advanced Hodgkin’s lymphoma patients are losing their meaning at the time of Pet-guided treatments 303
Calcium-Carbonate Nanocapsules Improve the Efficacy of BEZ235 in Lymphoma a Cell Line: A Promising New Technology of Drug Delivery 293
Dialysis-dependent renal failure at diagnosis continues to be associated with very poor outcome in multiple myeloma - response to Murphy et al 292
Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: Results of a large multicenter study involving 990 patients 284
Risk of second primary malignancy in breast cancer survivors: A nested population-based case-control study 272
Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis 268
Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis 266
Rational combinations of enzastaurin with novel targeted agents for patients with B-cell non-Hodgkin's lymphoma 261
Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma 261
Phase II Study of Velcade (R) Plus Mabthera (R) In Relapsed Follicular Lymphomas. 261
Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. 258
Anthracycline-Fludarabine Containing Regimens with or without Rituximab in the Treatment of Advanced Follicular Lymphoma Patients 257
Genomic profiling of enzastaurin-treated B cell lymphoma RL cells 255
Incidence and outcome of Myelodysplastic Syndromes in province of Modena 248
The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines 246
INCIDENCE AND SURVIVAL OF MYELOID MALIGNANCIES IN 1102 PATIENTS IN PROVINCE OF MODENA, NORTHERN ITALY 240
A RANDOMIZED PHASE II STUDY (GISL - MM03 TRIAL) WITH ORAL MELPHALAN+ PREDNISONE (MP) VERSUS MELPHALAN, + PREDNISONE + THALIDOMIDE (MPT) FOR NEWLY DIAGNOSED ELDERLY PATIENTS WITH MULTIPLE MYELOMA 237
Incidence and outcome of chronic myeloproliferative disorders: A population-based study from a cancer registry in northern Italy 235
Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: a large multicenter study involving 1191 patients, in the pre and post rituximab era 235
The potential of pralatrexate as a treatment of peripheral T-cell lymphoma 231
Khorana score and histotype predict the incidence of early venous thromboembolism (VTE) in Non Hodgkin Lymphoma (NHL). A pooled data analysis of twelve clinical trials of Fondazione Italiana Linfomi (FIL) 230
Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients 230
Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: A phase III randomized study by the fondazione Italiana linfomi 223
: Late toxicity and quality of life (QOL) after treatment for Hodgkin disease (HD): A Gruppo Italiano Studio Linfomi (GISL) cohort study on 223 patients 213
Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: Results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL) 212
Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era: an analysis from the FOLL05 trial of the Fondazione Italiana Linfomi 210
Is endoscopic ultrasound clinically useful for follow-up of gastric lymphoma? 209
Second Malignancy After Treatment for Non-Hodgkin Lymphoma: a Systematic Review and a Meta-Analysis of Population-Based and Cohort Studies 208
Secondary malignancies after treatment of aggressive non-Hodgkin lymphoma: A GISL cohort study on 1259 patients 205
SECOND MALIGNANCIES AFTER TREATMENT FOR INDOLENT LYMPHOMA: A 16 YEARS FOLLOW-UP STUDY 205
VALIDATION OF ABSOLUTE LYMPHOCYTE COUNT / REVISED IPI (ALC/R-IPI) SCORE MODEL, AS A PROGNOSTIC INDEX FOR DIFFUSE LARGE-B-CELL LYMPHOMA IN RITUXIMAB ERA 196
Rapid loss of response after withdrawal of treatment with azacitidine: A case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia 190
Introduction of Combined Chemotherapies Plus Rituximab (R) Has Improved Outcome of Previously Untreated and Relapsed Follicular Lymphoma (FL) Patients (pts).. 186
Improving the international prognostic index score using peripheral blood counts: Results of a large multicenter study involving 520 patients with diffuse large B cell lymphoma 179
NATURAL HISTORY OF CRYOGLOBULINEMIA FROM 2000 TO 2018 FROM THE LABORATORY POINT OF VIEW: AN ANALYSIS OF CRYOGLOBULIN CHARACTERISTICS IN A SINGLE CENTER. 178
Treatment of patients with recurrent follicular lymphoma with rituximab in combination with fludarabine and cyclophosphamide 165
Khorana score and histotype predicts incidence of early venous thromboembolism in Non-Hodgkin lymphomas: A Pooled-Data analysis of 12 clinical trials of fondazione italiana linfomi (FIL) 159
Management of lymphoma survivor patients in Italy: an evaluation by Fondazione Italiana Linfomi 159
Rituximab in combination with chemotherapy has improved survival of patients with follicular lymphoma 154
Obinutuzumab and miniCHOP for unfit patients with diffuse large B-cell lymphoma. A phase II study by Fondazione Italiana Linfomi 154
The prognostic role of end of treatment FDG-PET-CT in patients with diffuse large B cell lymphoma can be improved by considering it with absolute monocyte count at diagnosis 140
Impact of immunochemotherapy with R-bendamustine or R-CHOP for treatment naïve advanced-stage follicular lymphoma: A subset analysis of the FOLL12 trial by Fondazione Italiana Linfomi 139
Diagnosi di crioproteinemia: preziosa collaborazione tra laboratorio e clinica per la corretta gestione di una patologia rara 137
End of induction [18F]FDG PET is prognostic for progression-free survival and overall survival in follicular lymphoma patients enrolled in the FOLL12 trial 126
Early progression beyond first-line chemoimmunotherapy in follicular lymphoma: Insights from a Fondazione Italiana Linfoma (FIL) study 99
Pazopanib-related secondary polycythemia in metastatic myxofibrosarcoma: A case report and review of the literature 99
Correction to: The classic prognostic factors in advanced Hodgkin’s lymphoma patients are losing their meaning at the time of pet-guided treatments (Annals of Hematology, (2020), 99, 2, (277-282), 10.1007/s00277-019-03893-7) 98
The impact of healthy lifestyles on late sequelae in classical hodgkin lymphoma and diffuse large b-cell lymphoma survivors. A systematic review by the fondazione italiana linfomi 90
Management of adverse events and supportive therapy in relapsed/refractory multiple myeloma 88
Second Cancers in Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma. A Systematic Review by the Fondazione Italiana Linfomi 83
Management of multiple myeloma|Terapia del mieloma multiplo 74
Totale 18.067
Salva come PNG Salva come JPEG
Categoria #
all - tutte 67.714
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 67.714
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.077 0 0 0 0 0 0 138 233 118 251 224 113
2021/20221.487 62 110 181 64 28 119 83 112 150 112 266 200
2022/20231.396 152 185 113 141 152 196 25 131 180 13 66 42
2023/20241.099 58 38 75 106 232 72 199 101 33 19 63 103
2024/20253.171 104 40 76 245 645 494 220 181 361 119 255 431
2025/20263.646 406 254 440 794 1.106 417 229 0 0 0 0 0
Totale 18.067